In addition, rapamycin, the original mTOR blocker from which this adaptor protein was named, has been proven effective in the treatment of intractable SLE resistant to, or intolerant of, conventional immunosuppressants as reported by Lai et al. [97]. Here, MTOR is linked to systemic lupus erythematosus.